Newron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia Transcript

🌐 Seeking Alpha (United States) —

AI Summary

Newron Pharmaceuticals discussed an FDA clinical hold and safety concerns affecting its ENIGMA-TRS program for treatment-resistant schizophrenia. The item is a transcript concerning the drug-development program and its regulatory status.

Markets Health Newron Pharmaceuticals FDA clinical hold schizophrenia drug safety ENIGMA-TRS

Read original source →